There are a few common targets for CAR-T cell therapy in HCC, the most common being Glypican-3 (GPC3), a 70 kDa heparan sulfate proteoglycan, expressed in approximately 75% of HCC patients but not by normal hepatocytes. The gene discussed is CD44; the disease is hepatocellular carcinoma.